Design of the hCD3ε/hCD28 mouse

The double-humanized CD3ε/CD28 model was generated from intercrossing hCD3ε and hCD28 mice.

The CD3ε humanized model was developed to express the human epitope of the CD3ε chain, which is recognized by T-cell engagers (clone SP34). The rest of the extracellular domain is murine to preserve the amino acids involved in the interaction with CD3γ and CD3δ. Similarly, the transmembrane domains and the intracellular domains are murine to enable salt bridge interaction, interaction with the CD3ζ, and the signaling into mouse cells.

The humanized CD28 model, developed by Knockin at the mouse CD28 locus, expresses a chimeric CD28 with a human extracellular and murine transmembrane and intracellular domains. hCD28 expression displays a physiological regulation and expression pattern. This double-humanized model enables assessment of both compounds targeting human CD3ε and/or human CD28 in immunocompetent mice.

Applications in immuno-oncology

The hCD3ε/hCD28 mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human T-cell engager CD3ε(SP-34) and/or the immune checkpoint CD28 in fully immunocompetent mice.

hCD3ε/hCD28 features

  • Extracellular CD3ε N-terminal epitope is humanized
  • Conserved and functional interaction of CD3γ, CD3δ and CD3ζ subunits
  • The CD28 extracellular domain is entirely humanized
  • Physiological regulation and expression pattern of CD3ε and human CD28
  • Fully functional mouse immune system

Validation

Related ressources et publications

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
No results

Discover related products to

hCD3ε/hCD28

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
T-cell engager
CD3
Mouse

Pan hCD3

Pan hCD3 immunocompetent mice enable the efficacy assessment of T-cell engagers, to study cancer cell recognition, immunosuppressant therapies, etc.

Mouse
ICP
CD28
ICP (single-target)

hCD28

The hCD28 mouse enables the in vivo efficacy assessment and profiling of immuno-oncology agents targeting the human immune checkpoint CD28 in fully immunocompetent mice.

T-cell engager
CD3
Mouse

hCD3ε

hCD3ε immunocompetent mice enable the preclinical in vivo efficacy assessment of T-cell engagers, to study cancer cell recognition, immunosuppressant therapies, etc.

Preclinical double-humanized CD3ε/CD28 mouse model

Get in touch about

Let us know how we can help

In order to provide you the content requested, we need to store and process your personal data. If you consent to us storing your personal data for this purpose, please tick the checkbox below.

From time to time, we would like to contact you about our products and services, as well as other content that may be of interest to you. If you consent to us contacting you for this purpose, please tick below.

You can unsubscribe from these communications at any time. For more information on how to unsubscribe, our privacy practices, and how we are committed to protecting and respecting your privacy, please review our Privacy Policy.

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.